Kodiak Sciences Inc. (KOD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kodiak Sciences Inc. (KOD) trades at $39.84 with AI Score 22/100 (Grade F). Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for retinal diseases. Market cap: $2.49B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 6, 2026Analyst Coverage for KOD: KOD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KOD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KOD: 2/3 scored disciplines lean bearish. Dominant signal: Financial Safety weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Kodiak Sciences Inc. (KOD) Healthcare & Pipeline Overview
Kodiak Sciences Inc. specializes in developing advanced therapeutics for retinal diseases, leveraging innovative biopolymer technology to enhance treatment efficacy and patient outcomes in a rapidly evolving healthcare landscape.
What Is the Investment Thesis for KOD?
Kodiak Sciences Inc. presents a compelling investment thesis driven by its innovative product pipeline and substantial market opportunity in retinal disease therapeutics. The lead candidate, KSI-301, is positioned to capture significant market share in the wet AMD segment, projected to reach $8 billion by 2027. The ongoing Phase IIb/III trials are critical milestones that could lead to FDA approval, enhancing Kodiak's market presence and financial performance. Additionally, the company's preclinical candidates, KSI-501 and KSI-601, offer further growth opportunities in addressing diverse retinal conditions, potentially expanding its therapeutic portfolio. With a robust clinical pipeline and a market cap of $2.49B, Kodiak is well-placed to leverage its innovative technologies and address significant unmet medical needs, making it a noteworthy player in the biotechnology landscape.
Based on FMP financials and quantitative analysis
KOD Key Highlights
Market Cap of $2.49B, reflecting strong investor interest in innovative biopharmaceuticals.
- Lead product KSI-301 in Phase IIb/III trials, targeting a market projected to exceed $8 billion by 2027.
- Beta of 2.40, indicating higher volatility compared to the broader market, typical for clinical-stage biotech firms.
- No dividend yield, consistent with the growth-oriented strategy of reinvesting in R&D.
- 109 employees, indicating a focused team dedicated to advancing clinical trials and product development.
Who Are KOD's Competitors?
KOD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TNGX Tango Therapeutics, Inc. | $25.20 | -0.94% | $4.10B | — |
| ANAB AnaptysBio, Inc. | $57.23 | -3.43% | $1.69B | 38 |
| MYOV Myovant Sciences Ltd. | $26.98 | -0.04% | $2.62B | 71 |
| ADMA ADMA Biologics, Inc. | $9.81 | -2.34% | $2.27B | 91 |
| HRMY Harmony Biosciences Holdings, Inc. | $38.32 | -4.04% | $2.22B | 98 |
| VCEL Vericel Corporation | $42.11 | -3.35% | $2.16B | 94 |
| ARQT Arcutis Biotherapeutics, Inc. | $25.35 | -4.20% | $3.17B | 89 |
| MBX MBX Biosciences | $68.40 | +2.83% | $3.26B | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KOD's Key Strengths?
Robust pipeline with innovative product candidates targeting high unmet needs.
- Experienced management team with expertise in biopharmaceutical development.
- Strong market potential in the retinal disease segment.
What Are KOD's Weaknesses?
Clinical-stage company with no current revenue from product sales.
- High dependency on successful trial outcomes for future growth.
- Limited financial resources compared to larger pharmaceutical firms.
What Could Drive KOD Stock Higher?
Phase IIb/III clinical trial results for KSI-301 expected in Q3 2026.
- Development of KSI-501 and KSI-601 in preclinical stages.
- Potential strategic partnerships to enhance product development and market access.
What Are the Key Risks for KOD?
Financial-distress signal — its Altman Z-Score of -4.19 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory approval risks associated with clinical trial outcomes.
- Market competition from established and emerging biopharmaceutical companies.
- Financial risks due to reliance on external funding and investment.
What Are the Growth Opportunities for KOD?
- Growth opportunity 1: The lead product KSI-301 targets wet AMD, a condition affecting millions globally. With the market for AMD therapeutics projected to reach $8 billion by 2027, successful Phase IIb/III trial outcomes could position Kodiak as a leading provider in this lucrative segment, potentially capturing significant market share.
- Growth opportunity 2: KSI-501, a bispecific conjugate, aims to address retinal diseases with inflammatory components, expanding Kodiak's therapeutic offerings. The inflammatory retinal disease market is growing, with a projected value of $4 billion by 2026, providing a substantial opportunity for Kodiak to diversify its product portfolio and revenue streams.
- Growth opportunity 3: KSI-601, targeting dry AMD, represents another significant market opportunity. As dry AMD affects a large demographic, with an estimated 15 million cases in the U.S. alone, successful development and commercialization could further enhance Kodiak's market position and financial performance.
- Growth opportunity 4: Strategic partnerships with larger pharmaceutical companies could accelerate Kodiak's clinical development and market access. Collaborations can provide additional funding, resources, and expertise, enhancing the company's ability to bring its innovative products to market more efficiently.
- Growth opportunity 5: Increasing global awareness and screening for retinal diseases are likely to drive demand for effective treatments. As healthcare systems prioritize early intervention and management of eye diseases, Kodiak's innovative therapies could see increased adoption, further driving revenue growth.
What Threats Does KOD Face?
- Intense competition from established and emerging biopharmaceutical companies.
- Regulatory hurdles and uncertainties in the approval process.
- Market volatility impacting funding and investment in biotech firms.
What Are KOD's Competitive Advantages?
- Innovative biopolymer technology that enhances drug delivery and efficacy.
- Strong clinical pipeline with multiple candidates addressing significant market needs.
- Experienced leadership team with a track record in biopharmaceutical development.
- Focus on high-barrier-to-entry therapeutic areas with limited competition.
- Established relationships with key stakeholders in the healthcare ecosystem.
What Does KOD Do?
Founded in 2009 and headquartered in Palo Alto, California, Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing novel therapeutics for retinal diseases. Originally known as Oligasis, LLC, the company rebranded to Kodiak Sciences Inc. in September 2015 to reflect its commitment to pioneering innovative solutions in ophthalmology. Kodiak's lead product candidate, KSI-301, is an anti-vascular endothelial growth factor (VEGF) antibody biopolymer currently undergoing Phase IIb/III clinical trials for the treatment of wet age-related macular degeneration (AMD) and other serious retinal conditions, including diabetic macular edema and non-proliferative diabetic retinopathy. In addition to KSI-301, Kodiak is advancing its preclinical pipeline with KSI-501, a bispecific conjugate targeting retinal diseases with an inflammatory component, and KSI-601, a triplet inhibitor aimed at treating dry AMD. The company is strategically positioned in the biotechnology sector, focusing on high-need therapeutic areas with significant market potential. Kodiak's innovative approach combines cutting-edge science with a robust clinical development strategy, allowing it to address critical challenges in retinal disease management and improve patient outcomes.
What Products and Services Does KOD Offer?
- Research and develop therapeutics for retinal diseases.
- Conduct clinical trials to evaluate the safety and efficacy of product candidates.
- Focus on innovative biopolymer technology for enhanced treatment delivery.
- Target significant unmet medical needs in ophthalmology.
- Advance preclinical candidates to address a broader range of retinal conditions.
- Engage with regulatory bodies for product approvals and compliance.
How Does KOD Make Money?
- Generate revenue through the commercialization of approved therapeutics.
- Leverage partnerships and collaborations for funding and resource access.
- Focus on research and development to innovate and expand the product pipeline.
- Aim for licensing agreements post-approval to maximize market reach.
- Utilize a clinical trial strategy to gather data for regulatory submissions.
What Industry Does KOD Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in genetic research, personalized medicine, and increased healthcare spending. The retinal disease therapeutics market, in particular, is expected to expand significantly, with a projected CAGR of over 10% through 2027. Kodiak Sciences Inc. is well-positioned within this landscape, focusing on innovative treatments for retinal diseases, which are often underserved by existing therapies. The competitive landscape includes other biotech firms like Tango Therapeutics, Inc. (TNGX) and AnaptysBio, Inc. (ANAB), which are also targeting similar therapeutic areas, emphasizing the need for differentiation through innovative product development.
Who Are KOD's Key Customers?
- Healthcare providers specializing in ophthalmology.
- Patients suffering from retinal diseases.
- Pharmaceutical partners for collaborative development.
- Investors seeking opportunities in biopharmaceutical innovation.
- Regulatory agencies for product approvals.
Company Profile
Kodiak Sciences Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Palo Alto, US. The company is led by CEO Victor Perlroth. KOD has traded publicly since 2018.
How Kodiak Sciences Inc. Is Valued
Kodiak Sciences Inc. carries a market capitalization of $2.49B, placing it in the mid-cap category. Relative to its peer group, KOD's quantitative score of 22/100 is below the peer average of 75/100.
Key Financial Metrics
Return on assets is -75.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.54 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Kodiak Sciences Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.19 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Kodiak Sciences Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 4.0% below estimates on average.
Forward Outlook
Wall Street analysts project Kodiak Sciences Inc. revenue of about $11.3M for fiscal 2026, with EPS near $-3.71. The estimate reflects 3 contributing analysts.
KOD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Kodiak's recent insider buying suggests strong confidence from those closest to the company's operations, a potentially positive signal.
- The social trading community seems to be buzzing about potential catalysts for Kodiak, indicating heightened interest and speculative momentum.
- There's a growing perception that Kodiak's approach to retinal diseases could be a game-changer, driving positive sentiment.
- Kodiak's pipeline progress is being viewed favorably, with anticipation building around upcoming data releases.
Bear Case
- Some in the community are skeptical about the long-term efficacy of Kodiak's lead drug candidate compared to existing treatments.
- Recent market volatility has amplified concerns about the risk profile of biotech stocks like Kodiak, impacting investor appetite.
- There's a sense that Kodiak's success is heavily reliant on a single product, creating vulnerability if trials don't pan out.
- The community is wary of potential dilution from future funding rounds, which could weigh on the stock's performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
KOD Latest News
KOD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KOD.
Price Targets
Wall Street price target analysis for KOD.
KOD MoonshotScore
What does this score mean?
The MoonshotScore rates KOD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Victor Perlroth
Chief Executive Officer
Victor Perlroth has extensive experience in the biopharmaceutical sector, holding leadership roles in various innovative companies. He holds a degree in Molecular Biology from Stanford University and has a strong track record in driving product development and strategic growth initiatives.
Track Record: Under Victor's leadership, Kodiak Sciences has successfully advanced its clinical pipeline and secured significant funding to support its research efforts. His strategic vision has positioned the company for future growth in the competitive biotechnology landscape.
KOD Healthcare Stock FAQ
What does the AI Score mean for KOD?
KOD holds an AI Score of 22/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for retinal diseases. Its lead candidate, KSI-301, aims to address significant unmet …
What does Kodiak Sciences Inc. do?
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for retinal diseases. Its lead product candidate, KSI-301, is currently in Phase IIb/III trials targeting wet age-related macular degeneration, while the company also explores other candidates for various retinal conditions, aiming to address significant unmet medical needs in ophthalmology.
What do analysts say about KOD stock?
Analysts generally view KOD stock as a high-risk, high-reward investment, primarily due to its clinical-stage status and reliance on trial outcomes. Key valuation metrics include a market cap of $2.49B, with expectations for significant growth contingent on successful product development and regulatory approvals. Analysts highlight the potential for KSI-301 to capture substantial market share in the wet AMD segment.
What are the main risks for KOD?
Kodiak Sciences faces several risks, including the potential for unfavorable clinical trial outcomes that could delay or prevent product approvals. Additionally, the company operates in a competitive landscape with numerous established players, which may impact its market entry and pricing strategies. Financial sustainability is also a concern, as the company relies on external funding to support its ongoing research and development efforts.
What are the key factors to evaluate for KOD?
Kodiak Sciences Inc. (KOD) holds an AI score of 22/100 (low). presents a compelling investment thesis driven by its innovative product pipeline and substantial market opportunity in retinal disease therapeutics. Not financial advice.
How frequently does KOD data refresh on this page?
KOD's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KOD's recent stock price performance?
Kodiak Sciences Inc. (KOD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Robust pipeline with innovative product candidates targeting high unmet needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KOD overvalued or undervalued right now?
Kodiak Sciences Inc. (KOD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research KOD before investing?
Before investing in Kodiak Sciences Inc. (KOD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on the latest available data and may be subject to change.